Striae  ||| S:0 E:7 ||| NNP
after  ||| S:7 E:13 ||| IN
topical  ||| S:13 E:21 ||| JJ
corticosteroid ||| S:21 E:35 ||| NN
:  ||| S:35 E:37 ||| :
Treatment  ||| S:37 E:47 ||| NNP
with  ||| S:47 E:52 ||| IN
nonablative  ||| S:52 E:64 ||| FW
fractional  ||| S:64 E:75 ||| FW
laser  ||| S:75 E:81 ||| FW
1540nm  ||| S:81 E:88 ||| FW
Striae  ||| S:88 E:95 ||| FW
distensae  ||| S:95 E:105 ||| FW
are  ||| S:105 E:109 ||| VBP
atrophic  ||| S:109 E:118 ||| JJ
dermal  ||| S:118 E:125 ||| NNS
scars  ||| S:125 E:131 ||| VBP
associated  ||| S:131 E:142 ||| VBN
with  ||| S:142 E:147 ||| IN
psychosocial  ||| S:147 E:160 ||| JJ
stress ||| S:160 E:166 ||| NN
.  ||| S:166 E:168 ||| .
Several  ||| S:168 E:176 ||| JJ
treatments  ||| S:176 E:187 ||| NNS
have  ||| S:187 E:192 ||| VBP
been  ||| S:192 E:197 ||| VBN
used  ||| S:197 E:202 ||| VBN
but  ||| S:202 E:206 ||| CC
there  ||| S:206 E:212 ||| EX
is  ||| S:212 E:215 ||| VBZ
no  ||| S:215 E:218 ||| DT
gold  ||| S:218 E:223 ||| NN
standard  ||| S:223 E:232 ||| NN
until  ||| S:232 E:238 ||| IN
now ||| S:238 E:241 ||| RB
.  ||| S:241 E:243 ||| .
Fractional  ||| S:243 E:254 ||| JJ
photothermolysis  ||| S:254 E:271 ||| NN
has  ||| S:271 E:275 ||| VBZ
been  ||| S:275 E:280 ||| VBN
described  ||| S:280 E:290 ||| VBN
as  ||| S:290 E:293 ||| IN
a  ||| S:293 E:295 ||| DT
successful  ||| S:295 E:306 ||| JJ
and  ||| S:306 E:310 ||| CC
safe  ||| S:310 E:315 ||| JJ
method  ||| S:315 E:322 ||| NN
to  ||| S:322 E:325 ||| TO
treat  ||| S:325 E:331 ||| VB
scars ||| S:331 E:336 ||| NNS
.  ||| S:336 E:338 ||| .
In  ||| S:338 E:341 ||| IN
this  ||| S:341 E:346 ||| DT
description ||| S:346 E:357 ||| NN
,  ||| S:357 E:359 ||| ,
we  ||| S:359 E:362 ||| PRP
report  ||| S:362 E:369 ||| VBP
4  ||| S:369 E:371 ||| CD
patients  ||| S:371 E:380 ||| NNS
( ||| S:380 E:381 ||| -LRB-
Fitzpatrick  ||| S:381 E:393 ||| NNP
phototype  ||| S:393 E:403 ||| VBD
IV ||| S:403 E:405 ||| NNP
)  ||| S:405 E:407 ||| -RRB-
who  ||| S:407 E:411 ||| WP
developed  ||| S:411 E:421 ||| VBD
striae  ||| S:421 E:428 ||| JJ
distensae  ||| S:428 E:438 ||| NN
after  ||| S:438 E:444 ||| IN
long-term  ||| S:444 E:454 ||| JJ
use  ||| S:454 E:458 ||| NN
of  ||| S:458 E:461 ||| IN
topical  ||| S:461 E:469 ||| JJ
corticosteroids  ||| S:469 E:485 ||| NN
and  ||| S:485 E:489 ||| CC
were  ||| S:489 E:494 ||| VBD
successfully  ||| S:494 E:507 ||| RB
treated  ||| S:507 E:515 ||| VBN
with  ||| S:515 E:520 ||| IN
fractional  ||| S:520 E:531 ||| FW
nonablative  ||| S:531 E:543 ||| FW
1540  ||| S:543 E:548 ||| FW
nm  ||| S:548 E:551 ||| FW
Erbium ||| S:551 E:557 ||| FW
:  ||| S:557 E:559 ||| :
glass  ||| S:559 E:565 ||| NN
laser ||| S:565 E:570 ||| NN
.  ||| S:570 E:572 ||| .
